Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations

• Published in: Movement disorders Vol. 33; no. 5; pp. 660 - 677
• Main Authors: Lang, Anthony E., Espay, Alberto J.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.05.2018
• Subjects: alpha synuclein; Animals; Antiparkinson Agents - therapeutic use; Calcium; Clinical trials; Clinical Trials as Topic - methods; Clinical Trials as Topic - standards; Disease Management; disease modification; Disease Progression; Genetic variability; Glucagon; Glucosylceramidase; Humans; Immunization (passive); Lysosomes; Mitochondria; Movement disorders; Neurodegeneration; Neurodegenerative diseases; Neuroprostanes - therapeutic use; neuroprotection; Neurotoxicity; Organelles; Oxidative stress; Parkinson Disease - diagnosis; Parkinson Disease - genetics; Parkinson Disease - therapy; Parkinson's disease; pathogenesis; Patients; Synaptic transmission; Synuclein; pathogenesis; Parkinson's disease; alpha synuclein; neuroprotection; disease modification
• ISSN: 0885-3185; 1531-8257; 1531-8257
• DOI: 10.1002/mds.27360

ABSTRACT The greatest unmet therapeutic need in Parkinson's disease is the development of treatment that slows the relentless progression of the neurodegenerative process. The concept of “disease modification” encompasses intervention types ranging from those designed to slow the underlying deg...